Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer. In this post, I will discuss our most recent understanding of this aggressive disease.
almost all women with IBC have lymph node involvement at the time of diagnosis.
Tag: targeted therapy
Another PARP inhibitor showing promise
PARP inhibitors are unique molecules targeting only the PARP enzyme in BRCA 1/2 mutated cells, they are generally well tolerated as compared to chemotherapy. In this year at San Antonio Breast Cancer Symposium, the EMBRACA trial results were presented in abstract form.
The talazoparib arm patients reported better quality of life score as well as there was a significant delay in the time to deterioration